Genentech's Shifting Strategies and Emerging Biotechs

This chapter examines significant changes at Genentech, including the closure of its cancer immunology group and the implications of increased reliance on AI in drug discovery. It also highlights the rise of the Chinese biopharma company KSO and its partnership with Summit Therapeutics, showcasing innovative developments in immunotherapy. The discussion concludes with a light-hearted exchange, contrasting the serious topics of biotech with whimsical commentary on cake preferences.